Is Curis, Inc. (CRIS) a Buy, Sell, or Hold?
NASDAQ : CRIS
Curis, Inc.
$4.73 USD
$0.08 (1.72%)
- Volume
- 45.77K
- Average Volume
- 168.25K
- Market Capitalization
- $9.22M
- P/E Ratio
- -0.20
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $39.00
- Year Low
- $3.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
| Source | Headline |
|---|---|
|
Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study. prnewswire.com - 2026-07-06 09:30:00 |
|
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever gurufocus.com - 2026-06-26 10:00:00 |
|
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia. prnewswire.com - 2026-06-26 09:42:00 |
|
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-13 04:20:45 |
|
Curis Provides First Quarter 2026 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass. prnewswire.com - 2026-05-12 16:00:00 |
|
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m. prnewswire.com - 2026-05-05 17:11:00 |
|
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago. zacks.com - 2026-04-28 09:46:12 |
